Colorectal Cancer
Conditions
Keywords
colorectal cancer, first line, folfirinox + cetuximab
Brief summary
This retrospective study, will evaluate patient outcomes after triplet chemotherapy (FOLFIRINOX) (5 Fluorouracil + oxaliplatin + irinotecan) plus cetuximab 1st line treatment focusing on efficacy and safety in a RAS (KRAS, NRAS (neuroblastoma rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer population, and according to BRAF (murine sarcoma viral oncogene homolog B) status and primary tumor location.
Detailed description
In Europe, there are 447,000 new cases of colorectal cancer each year. Approximately 25% of patients present with metastases at initial diagnosis and almost 50% of patients with mCRC (metastatic colorectal cancer) will develop metastases . Chemotherapy represents the backbone of treatment, and survival is linked with the administration of all three active cytotoxic agents (5-fluorouracil/folinate, oxaliplatin, and irinotecan) in the first line treatment of metastatic colorectal disease. Monoclonal antibodies such as cetuximab in combination with chemotherapy are a first line treatment option in metastatic RAS (rat sarcoma viral oncogene homolog) wild type metastatic colorectal cancer (mCRC). Phase II trials evaluating triplet chemotherapy plus cetuximab reported interesting results in terms of efficacy (response rate, resectability...), but at the price of an increased rate of toxic effects. This retrospective study, will evaluate patient outcomes after triplet chemotherapy (FOLFIRINOX) (5 Fluorouracil + oxaliplatin + irinotecan) plus cetuximab 1st line treatment focusing on efficacy and safety in a RAS (KRAS, NRAS (neuroblastoma rat sarcoma viral oncogene homolog) wild-type mCRC (metastatic colorectal cancer) population, and according to BRAF (murine sarcoma viral oncogene homolog B) status and primary tumor location.
Interventions
DRUGFolfirinox + cetuximab
Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
Sponsors
Merck Serono International SA
Institut du Cancer de Montpellier - Val d'Aurelle
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Colorectal cancer confirmed as RAS wild by tumor tissue analysis 2. Non resectable and measurable metastatic disease 3. Patients treated with FOLFIRINOX + cetuximab in first line metastatic disease 4. Males or females aged over 18 years.
Exclusion criteria
1. Known brain metastases 2. RAS not assessable (e.g., material not available or insufficient) 3. The first administration of cetuximab was more than 30 days after the first administration of FOLFIRINOX 4. History of other malignancy in the last 5 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Median Progression free survival (PFS) | Approximately 36 months | In RAS wt population |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | Maximal 6 months | at the end of 1st line treatment evaluated according RECIST ( Response Evaluation Criteria in Solid Tumours) |
| Overall Survival | Approximately 36 months | Defined as the time from the date of initial first line treatment initiation to the date of documented death from any cause |
| Progression free survival (PFS) | 9 months | Rates in RAS wt population |
| Assessment of adverse events by using the NCI-CTCAE version 4.0 scale | Maximal 6 months | Maximum grade observed throughout the treatment |
| Liver metastases resection rate | Maximal 6 months | Resection (R0 / R1 / R2) |
| Duration of response | Approximately 36 months | — |
Countries
France
Outcome results
None listed